The Indian Council of Medical Research (ICMR) has obtained permission for “restricted use in public health emergency” of two second-line HIV medications for use against the novel coronavirus (nCoV)

Despite Nipah virus outbreaks having high mortality rates (>70% in Southeast Asia), there are no licensed drugs against it.

Question raised in Lok Sabha on Drug Resistant TB Cases, 06/12/2019. India has the largest number of individuals suffering from drug resistant TB. However, as per the latest global TB report, India ranks 38th in the number of MDR-TB patients per lakh population (9.6 per lakh population).

The key objective of this research was to generate new evidence on outpatient antibiotic prescription rate and patterns in the private sector in India. We used 12-month period (May 2013 to April 2014) medical audit dataset from IQVIA (formerly IMS Health).

The bi-directional relationship between poverty and tuberculosis (TB) is well established. Poverty aggravates material disadvantage, social exclusion, discrimination in participation across a wide range of socio-economic and behavioural activities along with undernutrition, overcrowding, lack of access to healthcare and other social determinants of health.

According to the World Health Organisation (WHO), Colistin is a “reserve” antibiotic, which means it is supposed to be considered a “last-resort” option in treatment and used only in the most sever

These rules aim to make available a database of clinical establishments which are authorised to function and thereby improve public health quality by eliminating quacks

In light of established principles and strategies for appropriate use of antimicrobial medicines, this paper examines studies on antimicrobial use trends across several countries in the Asia and Pacific regions.

Antimicrobial resistance (AMR) – in which a microorganism (such as a bacterium, virus, fungus or parasite) becomes resistant to an antimicrobial drug used to treat infections caused by it – is possibly the most serious public health threat of our time.

MUMBAI: Pharma major Gilead Sciences has failed to deliver on promises to make an important drug available to patients suffering from a life-threatening HIV-related infection in certain developing

Pages